Test Catalog

Test Id : GNPLT

Platelet Disorders, Comprehensive Gene Panel, Next-Generation Sequencing, Varies

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluating hereditary platelet disorders in patients with a personal or family history suggestive of a hereditary platelet disorder

 

Diagnosing hereditary platelet disorders for patients in whom phenotypic testing is nondiagnostic, but there is a strong clinical suspicion of the hereditary platelet disorder

 

Confirming a hereditary platelet disorder diagnosis with the identification of a known or suspected disease-causing alteration in one or more of 70 genes associated with a variety of hereditary platelet disorders

 

Determining the disease-causing alterations within one or more of these 70 genes to delineate the underlying molecular defect in a patient with a laboratory diagnosis of a platelet disorder

 

Identifying the causative alteration for genetic counseling purposes

 

Prognosis and risk assessment based on the genotype-phenotype correlations

 

Providing a prognosis in syndromic hereditary platelet disorders

 

Carrier testing for close family members of an individual with a hereditary platelet disorder diagnosis

 

This test is not intended for prenatal diagnosis.

Genetics Test Information
Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 70 genes associated with a variety of hereditary platelet disorders: ABCC4, ABCG5, ABCG8, ACTB, ACTN1, ANKRD26, ANO6, AP3B1, AP3D1, ARPC1B, BLOC1S3, BLOC1S5, BLOC1S6, CDC42, CYCS, DIAPH1, DTNBP1, ETV6, FERMT3, FLI1, FLNA, FYB1, GATA1, GATA2, GFI1B, GNE, GP1BA, GP1BB, GP6, GP9, HOXA11, HPS1, HPS3, HPS4, HPS5, HPS6, IKZF5, ITGA2B, ITGB3, KDSR, LYST, MASTL, MECOM, MPIG6B, MPL, MYH9, NBEA, NBEAL2, ORAI1, P2RY1, P2RY12, PLA2G4A, PLAU, PRKACG, PTGS1, RASGRP2, RBM8A, RUNX1, SLFN14, SRC, STIM1, STXBP2, TBXA2R, TBXAS1, THPO, TPM4, TUBB1, VIPAS39, VPS33B, and WAS. See Targeted Genes and Methodology Details for Platelet Disorders Comprehensive Gene Panel and Method Description for additional details.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for a variety of hereditary platelet disorders.

Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test Id Reporting Name Available Separately Always Performed
CULFB Fibroblast Culture for Genetic Test Yes No

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

The clinical workup for detecting inherited platelet disorders should begin with a careful review of the complete blood cell count and peripheral blood smear results as well as other platelet tests, such as light transmission platelet aggregometry electrical impedance whole blood aggregometry, platelet function analyzer 100 (PFA-100), platelet transmission electron microscopy (TEM) and platelet flow cytometric analysis. TEM is an essential tool for laboratory diagnosis of various hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome. Flow cytometry is the preferred method to assess hereditary platelet disorders due to quantitative surface glycoprotein deficiencies.

 

Platelet laboratory testing may not be able to identify all inherited platelet disorders. Occasionally, the clinical picture may be consistent with a defect in primary hemostasis, but the results of platelet function tests may be normal or non-diagnostic.

 

Genetic testing for hereditary platelet disorders is indicated if:

-Platelet tests indicate a deficiency or functional abnormality

-There is a clinical suspicion for a hereditary platelet disorder due to family history or patient’s clinical presentation

-Acquired causes of deficiencies associated with platelet disorders have been excluded

 

If a platelet disorder is a concern, a set of clinical guidelines from the British Society for Haematology on testing for heritable platelet disorders is freely available.(1)

 

For skin biopsy or cultured fibroblast specimens:

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

Method Name
A short description of the method used to perform the test

Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Platelet Comprehensive Panel, NGS

Aliases
Lists additional common names for a test, as an aid in searching

NextGen Sequencing Test

Hereditary platelet disorders

Hereditary/Congenital thrombocytopenia

Hereditary platelet storage pool deficiencies

Reduced ADP-induced platelet aggregation

Sitosterolemia with macrothrombocytopenia

Baraitser-Winter syndrome 1 with macrothrombocytopenia

Macrothrombocytopenia

Autosomal dominant thrombocytopenia 2

Scott syndrome

Hermansky-Pudlak syndrome

Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease

Takenouchi-Kosaki syndrome with thrombocytopenia

Autosomal dominant thrombocytopenia 4

Macrothrombocytopenia and sensorineural hearing loss

Thrombocytopenia and susceptibility to cancer

Leukocyte integrin adhesion deficiency, type III

Paris-Trousseau thrombocytopenia

Jacobsen syndrome

Syndrome with macrothrombocytopenia

Thrombocytopenia 3

X-linked GATA-1 variant

X-linked thrombocytopenia with dyserythropoiesis

GATA2 deficiency

Platelet-type bleeding disorder 17

Myopathy associated with thrombocytopenia

Bernard-Soulier syndrome

Mild macrothrombocytopenia

Platelet-type von Willebrand disease

Bleeding diathesis due to glycoprotein VI deficiency

Amegakaryocytic thrombocytopenia with radioulnar synostosis

Glanzmann thrombasthenia

Platelet-type bleeding disorder 16

Thrombocytopenia and erythrokeraderma

CHS1

Chediak-Higashi syndrome

Autosomal Thrombocytopenia with Normal Platelets

Amegakaryocytic thrombocytopenia with radioulnar synostosis 2

Thrombocytopenia, anemia and myelofibrosis

Congenital amegakaryocytic thrombocytopenia (CAMT)

May-Hegglin disorder/anomaly

Sebastian syndrome

MYH9-related disorders

Autism with platelet dense granule defect

Gray platelet syndrome

Autosomal dominant tubular aggregate myopathy-2

Thrombosis/bleeding

ADP receptor defect

Deficiency of phospholipase A2, group IV A

Quebec platelet disorder

Platelet-type bleeding disorder 19

Aspirin-like defect (ALD)

Platelet-type bleeding disorder 12

Platelet-type bleeding disorder 18

Thrombocytopenia-absent radius syndrome

Familial platelet disorder with predisposition to AML

Platelet-type bleeding disorder 20

Thrombocytopenia 6

Stormorken syndrome

York platelet syndrome

Familial hemophagocytic lymphohistiocytosis type 5

Thromboxane A2 receptor defect

Ghosal syndrome

Thrombocytopenia progressing to trilineage bone marrow failure

ARC syndrome (Arthrogryposis, renal dysfunction, and cholestasis) 1

ARC syndrome (Arthrogryposis, renal dysfunction, and cholestasis) 2

Wiskott-Aldrich syndrome

Storage pool deficiency, not otherwise specified

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

The clinical workup for detecting inherited platelet disorders should begin with a careful review of the complete blood cell count and peripheral blood smear results as well as other platelet tests, such as light transmission platelet aggregometry electrical impedance whole blood aggregometry, platelet function analyzer 100 (PFA-100), platelet transmission electron microscopy (TEM) and platelet flow cytometric analysis. TEM is an essential tool for laboratory diagnosis of various hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome. Flow cytometry is the preferred method to assess hereditary platelet disorders due to quantitative surface glycoprotein deficiencies.

 

Platelet laboratory testing may not be able to identify all inherited platelet disorders. Occasionally, the clinical picture may be consistent with a defect in primary hemostasis, but the results of platelet function tests may be normal or non-diagnostic.

 

Genetic testing for hereditary platelet disorders is indicated if:

-Platelet tests indicate a deficiency or functional abnormality

-There is a clinical suspicion for a hereditary platelet disorder due to family history or patient’s clinical presentation

-Acquired causes of deficiencies associated with platelet disorders have been excluded

 

If a platelet disorder is a concern, a set of clinical guidelines from the British Society for Haematology on testing for heritable platelet disorders is freely available.(1)

 

For skin biopsy or cultured fibroblast specimens:

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

Specimen Type
Describes the specimen type validated for testing

Varies

Ordering Guidance

The test is designed to evaluate a variety of hereditary platelet disorders and to be utilized for genetic confirmation of a phenotypic diagnosis of a hereditary platelet disorder.

 

This test is not designed to evaluate for hereditary bleeding disorders. For patients with clinical suspicion of an inherited bleeding disorder, it is important to exclude plasmatic factor deficiencies e.g., von Willebrand disease, hemophilia, or other factor deficiencies prior to considering an inherited platelet function defect. If bleeding is the indication for testing and testing for hereditary bleeding disorders is desired, bleeding panels are available. See GNBLF / Bleeding Focused Gene Panel or GNBLC / Bleeding Comprehensive Panel.

 

For assessment of hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome, order PTEM / Platelet Transmission Electron Microscopic Study, Whole Blood.

 

For assessment of hereditary platelet disorders due to quantitative surface glycoprotein deficiencies, order PLAFL / Platelet Glycoprotein Flow Platelet Surface Glycoprotein by Flow Cytometry, Blood.

 

Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

Shipping Instructions

Specimen preferred to arrive within 96 hours of collection.

Necessary Information

Platelet Esoteric Testing Patient Information is required. Testing may proceed without the patient information; however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

 

Submit only 1 of the following specimens:

 

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated

 

Specimen Type: Skin biopsy

Supplies: Fibroblast Biopsy Transport Media (T115)

Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.

Specimen Volume: 4-mm punch

Specimen Stability Information: Refrigerated (preferred)/Ambient

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.

 

Specimen Type: Cultured fibroblasts

Container/Tube: T-25 flask

Specimen Volume: 2 Flasks

Collection Instructions: Submit confluent cultured fibroblast cells from a skin biopsy from another laboratory. Cultured cells from a prenatal specimen will not be accepted.

Specimen Stability Information: Ambient (preferred)/Refrigerated (<24 hours)

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

1. Platelet Esoteric Testing Patient Information is required.

2. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

3. If not ordering electronically, complete, print, and send an Coagulation Test Request (T753) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.

Blood: 1 mL; Cultured fibroblasts/skin biopsy: see Specimen Required

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Varies Varies

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluating hereditary platelet disorders in patients with a personal or family history suggestive of a hereditary platelet disorder

 

Diagnosing hereditary platelet disorders for patients in whom phenotypic testing is nondiagnostic, but there is a strong clinical suspicion of the hereditary platelet disorder

 

Confirming a hereditary platelet disorder diagnosis with the identification of a known or suspected disease-causing alteration in one or more of 70 genes associated with a variety of hereditary platelet disorders

 

Determining the disease-causing alterations within one or more of these 70 genes to delineate the underlying molecular defect in a patient with a laboratory diagnosis of a platelet disorder

 

Identifying the causative alteration for genetic counseling purposes

 

Prognosis and risk assessment based on the genotype-phenotype correlations

 

Providing a prognosis in syndromic hereditary platelet disorders

 

Carrier testing for close family members of an individual with a hereditary platelet disorder diagnosis

 

This test is not intended for prenatal diagnosis.

Genetics Test Information
Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 70 genes associated with a variety of hereditary platelet disorders: ABCC4, ABCG5, ABCG8, ACTB, ACTN1, ANKRD26, ANO6, AP3B1, AP3D1, ARPC1B, BLOC1S3, BLOC1S5, BLOC1S6, CDC42, CYCS, DIAPH1, DTNBP1, ETV6, FERMT3, FLI1, FLNA, FYB1, GATA1, GATA2, GFI1B, GNE, GP1BA, GP1BB, GP6, GP9, HOXA11, HPS1, HPS3, HPS4, HPS5, HPS6, IKZF5, ITGA2B, ITGB3, KDSR, LYST, MASTL, MECOM, MPIG6B, MPL, MYH9, NBEA, NBEAL2, ORAI1, P2RY1, P2RY12, PLA2G4A, PLAU, PRKACG, PTGS1, RASGRP2, RBM8A, RUNX1, SLFN14, SRC, STIM1, STXBP2, TBXA2R, TBXAS1, THPO, TPM4, TUBB1, VIPAS39, VPS33B, and WAS. See Targeted Genes and Methodology Details for Platelet Disorders Comprehensive Gene Panel and Method Description for additional details.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for a variety of hereditary platelet disorders.

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

The clinical workup for detecting inherited platelet disorders should begin with a careful review of the complete blood cell count and peripheral blood smear results as well as other platelet tests, such as light transmission platelet aggregometry electrical impedance whole blood aggregometry, platelet function analyzer 100 (PFA-100), platelet transmission electron microscopy (TEM) and platelet flow cytometric analysis. TEM is an essential tool for laboratory diagnosis of various hereditary platelet disorders that have ultrastructural abnormalities, such as gray platelet syndrome. Flow cytometry is the preferred method to assess hereditary platelet disorders due to quantitative surface glycoprotein deficiencies.

 

Platelet laboratory testing may not be able to identify all inherited platelet disorders. Occasionally, the clinical picture may be consistent with a defect in primary hemostasis, but the results of platelet function tests may be normal or non-diagnostic.

 

Genetic testing for hereditary platelet disorders is indicated if:

-Platelet tests indicate a deficiency or functional abnormality

-There is a clinical suspicion for a hereditary platelet disorder due to family history or patient’s clinical presentation

-Acquired causes of deficiencies associated with platelet disorders have been excluded

 

If a platelet disorder is a concern, a set of clinical guidelines from the British Society for Haematology on testing for heritable platelet disorders is freely available.(1)

 

For skin biopsy or cultured fibroblast specimens:

For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Platelets have essential roles in primary hemostasis. Patients with either hereditary or acquired platelet disorders usually have bleeding diathesis, which can potentially be life-threatening and may also have issues with the development and/or functioning of major organs.(2) Inherited platelet disorders can be syndromic (ie, associated with current or future development of other organ system defects) or non-syndromic (ie, isolated to thrombocytopenia with no other organ system defects).

 

A reliable laboratory diagnosis of a platelet disorder can significantly impact patients' and, potentially, their family members' clinical management and outcome. Identification of an alteration that is known or suspected to cause disease aids in confirmation of the diagnosis and potentially provides prognostic information especially in the syndromic inherited platelet disorders.

 

This panel evaluates 70 genes associated with a variety of hereditary platelet disorders, including reduced adenosine diphosphate (ADP)-induced platelet aggregation; Baraitser-Winter syndrome 1 with macrothrombocytopenia; Scott syndrome; Hermansky-Pudlak syndrome; platelet abnormalities with eosinophilia and immune-mediated inflammatory disease; Takenouchi-Kosaki syndrome with thrombocytopenia; leukocyte integrin adhesion deficiency type III; Paris-Trousseau-Jacobsen syndrome; GATA2 deficiency; Bernard-Soulier syndrome; platelet-type von Willebrand disease; bleeding diathesis due to glycoprotein VI deficiency; Glanzmann thrombasthenia; Chediak-Higashi syndrome; congenital amegakaryocytic thrombocytopenia; May-Hegglin disorder/anomaly; Sebastian syndrome; MYH9-related disorders; autism with platelet dense granule defect; gray platelet syndrome; autosomal dominant tubular aggregate myopathy-2; ADP receptor defect; deficiency of phospholipase A2 group IV A; Quebec platelet disorder; aspirin-like defect; thrombocytopenia-absent radius syndrome; familial platelet disorder with predisposition to acute myeloid leukemia; Stormorken syndrome; York platelet syndrome; familial hemophagocytic lymphohistiocytosis type 5; thromboxane A2 receptor defect; Ghosal syndrome; ARC (arthrogryposis, renal dysfunction, and cholestasis) syndromes 1 and 2; Wiskott-Aldrich syndrome; a variety of platelet-type bleeding disorders; and hereditary/congenital thrombocytopenias, such as various macrothrombocytopenias. These congenital thrombocytopenias include sitosterolemia with macrothrombocytopenia; macrothrombocytopenia and sensorineural hearing loss; thrombocytopenia and susceptibility to cancer; X-linked thrombocytopenia with dyserythropoiesis; myopathy associated with thrombocytopenia; amegakaryocytic thrombocytopenia with radioulnar synostoses 1 and 2; thrombocytopenia and erythrokeraderma; thrombocytopenia anemia and myelofibrosis; and thrombocytopenia progressing to trilineage bone marrow failure.

 

The risk for developing bleeding or other phenotypic features associated with these disorders and syndromes varies. Several of the genes on this panel have established bleeding, thrombocytopenia, and other hematologic or nonhematologic disease associations. Several of the genes on this panel also have expert group guidelines.(1,3-5)

 

It is recommended that genetic testing be offered to all patients suspected of having a heritable platelet disorder since some patients may have normal platelet laboratory testing results.(1,6)

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation
Provides information to assist in interpretation of the test results

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(7) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Clinical Correlations:

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

 

If testing was performed because of a clinically significant family history, it is often useful to first test an affected family member. Detection of a reportable variant in an affected family member would allow for more informative testing of at-risk individuals.

 

To discuss the availability of additional testing options or for assistance in the interpretation of these results, contact the Mayo Clinic Laboratories genetic counselors at 800-533-1710.

 

Technical Limitations:

Next-generation sequencing may not detect all types of genomic variants. In rare cases, false-negative or false-positive results may occur. The depth of coverage may be variable for some target regions; assay performance below the minimum acceptable criteria or for failed regions will be noted. Given these limitations, negative results do not rule out the diagnosis of a genetic disorder. If a specific clinical disorder is suspected, evaluation by alternative methods can be considered.

 

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. Confirmation of select reportable variants will be performed by alternate methodologies based on internal laboratory criteria.

 

This test is validated to detect 95% of deletions up to 75 base pairs (bp) and insertions up to 47 bp. Deletions-insertions (delins) of 40 or more bp, including mobile element insertions, may be less reliably detected than smaller delins.

 

Deletion/Duplication Analysis:

This analysis targets single and multi-exon deletions/duplications; however, in some instances, single exon resolution cannot be achieved due to isolated reduction in sequence coverage or inherent genomic complexity. Balanced structural rearrangements (such as translocations and inversions) may not be detected.

 

This test is not designed to detect low levels of mosaicism or differentiate between somatic and germline variants. If there is a possibility that any detected variant is somatic, additional testing may be necessary to clarify the significance of results.

 

For detailed information regarding gene specific performance and technical limitations, see Method Description or contact a laboratory genetic counselor.

 

If the patient has had an allogeneic hematopoietic stem cell transplant or a recent blood transfusion, results may be inaccurate due to the presence of donor DNA. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

 

Reclassification of Variants:

Currently, it is not standard practice for the laboratory to systematically review previously classified variants on a regular basis. The laboratory encourages healthcare providers to contact the laboratory at any time to learn how the classification of a particular variant may have changed over time. Due to broadening genetic knowledge, it is possible that the laboratory may discover new information of relevance to the patient. Should that occur, the laboratory may issue an amended report.

 

Variant Evaluation:

Evaluation and categorization of variants are performed using published American College of Medical Genetics and Genomics and the Association for Molecular Pathology recommendations as a guideline.(7) Other gene-specific guidelines may also be considered. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. Variants classified as benign or likely benign are not reported.

 

Multiple in silico evaluation tools may be used to assist in the interpretation of these results. The accuracy of predictions made by in silico evaluation tools is highly dependent upon the data available for a given gene, and periodic updates to these tools may cause predictions to change over time. Results from in silico evaluation tools should be interpreted with caution and professional clinical judgment.

 

Rarely, incidental or secondary findings may implicate another predisposition or presence of active disease. These findings will be carefully reviewed to determine whether they will be reported.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Gomez K, Anderson J, Baker P, et al: Clinical and laboratory diagnosis of heritable platelet disorders in adults and children: a British Society for Haematology Guideline. Brit J Haematol. 2021 Oct;195(1):46-72

2. Nurden AT, Freson K, Selifsohn U: Inherited platelet disorders. Haemophilia. 2012 July;18(s4):154-160

3. International Society on Thrombosis and Haemostasis: Bleeding Thrombotic and Platelet Disorder TIER1 genes. ISTH; 2018. Updated July 2022. Accessed October 6, 2022. Available at: www.isth.org/page/GinTh_GeneLists

4. Megy K, Downes K, Simeoni I, et al: Curated disease-causing genes for bleeding, thrombotic, and platelet disorders: Communication from the SSC of the ISTH. J Thromb Haemost. 2019 Aug;17(8):1253-1260

5. Bolton-Maggs PHB, Chalmers EA, Collins PW, et al: A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Brit J Haematol. 2006 Dec;135(5):603-633

6. Watson SP, Lowe GC, Lordkipanidze M, Morgan NV, GAPP consortiuml: Genotyping and phenotyping of platelet function disorders. J Thromb Haemost. 2013 June;11 Suppl 1:351-363

7. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424

Method Description
Describes how the test is performed and provides a method-specific reference

Next-generation sequencing (NGS) and/or Sanger sequencing is performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed, as well as some other regions that have known disease-causing variants. The human genome reference GRCh37/hg19 build was used for sequence read alignment. At least 99% of the bases are covered at a read depth over 30X. Sensitivity is estimated at above 99% for single nucleotide variants, above 94% for deletions-insertions (delins) less than 40 base pairs (bp), above 95% for deletions up to 75 bp and insertions up to 47 bp. NGS and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed.

 

There may be regions of genes that cannot be effectively evaluated by sequencing or deletion and duplication analysis as a result of technical limitations of the assay, including regions of homology, high guanine-cytosine (GC) content, and repetitive sequences. See Targeted Genes and Methodology Details for Platelet Disorders Comprehensive Gene Panel and Methodology Details for details regarding the targeted genes analyzed for each test and specific gene regions not routinely covered.(Unpublished Mayo method)

 

Reference transcript numbers may be updated due to transcript re-versioning. Always refer to the final patient report for gene transcript information referenced at the time of testing. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

 

Genes analyzed: ABCC4, ABCG5, ABCG8, ACTB, ACTN1, ANKRD26, ANO6, AP3B1, AP3D1, ARPC1B, BLOC1S3, BLOC1S5, BLOC1S6, CDC42, CYCS, DIAPH1, DTNBP1, ETV6, FERMT3, FLI1, FLNA, FYB1, GATA1, GATA2, GFI1B, GNE, GP1BA, GP1BB, GP6, GP9, HOXA11, HPS1, HPS3, HPS4, HPS5, HPS6, IKZF5, ITGA2B, ITGB3, KDSR, LYST, MASTL, MECOM, MPIG6B, MPL, MYH9, NBEA, NBEAL2, ORAI1, P2RY1, P2RY12, PLA2G4A, PLAU, PRKACG, PTGS1, RASGRP2, RBM8A, RUNX1, SLFN14, SRC, STIM1, STXBP2, TBXA2R, TBXAS1, THPO, TPM4, TUBB1, VIPAS39, VPS33B, and WAS

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

Supplemental

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

Varies

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

28 to 42 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

Whole blood: 2 weeks (if available); Extracted DNA: 3 months; Cultured fibroblasts: 1 month

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

81443

88233-Tissue culture, skin, solid tissue biopsy (if appropriate)

88240-Cryopreservation (if appropriate)

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
GNPLT Platelet Comprehensive Panel, NGS 105334-7
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
619286 Test Description 62364-5
619287 Specimen 31208-2
619288 Source 31208-2
619289 Result Summary 50397-9
619290 Result 82939-0
619291 Interpretation 59465-5
619292 Additional Results 82939-0
619293 Resources 99622-3
619294 Additional Information 48767-8
619295 Method 85069-3
619296 Genes Analyzed 82939-0
619297 Disclaimer 62364-5
619298 Released By 18771-6

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
Test Status - Test Resumed 2024-08-27
Test Status - Test Delay 2023-09-13